Patient-Centered Formularies: Steps in the Right Direction, but Challenges Remain

In a post on the IVI-sponsored Health Affairs featured blog series, Drugs and Medical Innovation, Jason Shafrin (IVI Director of Research) and Mark Linthicum (IVI Director of Scientific Communications) explore the role that formularies play in determining value for different stakeholders, and how unique, multi-stakeholder efforts can make formularies more patient-centered. Read the full article […]

Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value

In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular […]

Putting More Value Into Biopharmaceutical Value Assessments

In a commentary for the Health Affairs Blog, Rena M. Conti, PhD, and IVI Executive Director, Darius Lakdawalla, argue that advancing the science of value assessment requires new assessment tools that are transparent and incorporate the perspectives of patients and insurance plan enrollees. Read the full article here.

To Get Our Money’s Worth in Healthcare, We Need to Collaborate

In a commentary for Modern Healthcare, IVI Director of Scientific Communications, Mark Linthicum, emphasizes that the healthcare system needs to embrace collaboration to find consensus in the way we measure and pay for health care value. Read the full article here.

Well-Informed Patients Play a Key Role in Value-Based Care

In a commentary for Morning Consult, Virginia Ladd, President and Executive Director of the American Autoimmune Related Diseases Association (AARDA), emphasizes how critical it is that the patient perspective be front and center in discussions about how we measure and pay for value. Read the full article here.

An Open-Source Consensus-Based Approach to Value Assessment

In a commentary for the Health Affairs Blog, IVI’s Jeroen Jansen, Devin Incerti, and Mark Linthicum argue that, in order to move toward consensus on value assessment, the process for defining and measuring value must be transparent, collaborative, and iterative. IVI is taking the first steps towards consensus with the development of the Open-Source Value Project. […]

Shafrin Defines Precision Medicine for U.S. News and World Report

In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI’s Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through […]

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative’s latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible […]

Discussing the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, Anupam Jena (part of IVI’s scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model […]